Manageable early toxicity of cetuximab concurrent with radical radiotherapy for locally advanced head and neck cancer.

Suppr

超能文献

作者信息

Wieczorek A, Hamid A, O'Toole L

出版信息

Clin Oncol (R Coll Radiol). 2011 Sep;23(7):496. doi: 10.1016/j.clon.2011.03.004. Epub 2011 Apr 11.

DOI:10.1016/j.clon.2011.03.004

PMID:21482459

Abstract

摘要

相似文献

Manageable early toxicity of cetuximab concurrent with radical radiotherapy for locally advanced head and neck cancer.

Clin Oncol (R Coll Radiol). 2011 Sep;23(7):496. doi: 10.1016/j.clon.2011.03.004. Epub 2011 Apr 11.

Cetuximab and radiotherapy for head and neck cancer.

N Engl J Med. 2006 Feb 9;354(6):634-6. doi: 10.1056/NEJMe058306.

More on cetuximab in head and neck cancer.

N Engl J Med. 2007 Nov 22;357(21):2201-2; author reply 2202-3. doi: 10.1056/NEJMc071540.

Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer.

Radiother Oncol. 2009 Dec;93(3):654. doi: 10.1016/j.radonc.2009.05.005. Epub 2009 Jun 11.

Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer.

Clin Oncol (R Coll Radiol). 2008 Nov;20(9):717. doi: 10.1016/j.clon.2008.07.003. Epub 2008 Aug 30.

Cetuximab plus radiotherapy for head and neck cancer.

N Engl J Med. 2006 May 18;354(20):2187; author reply 2187.

Cetuximab plus radiotherapy for head and neck cancer.

N Engl J Med. 2006 May 18;354(20):2187; author reply 2187.

Head and neck cancer: integrating anti-EGFR treatment with standard therapy.

J Natl Compr Canc Netw. 2004 Sep;2 Suppl 2:S52-9.

Cetuximab plus radiotherapy for head and neck cancer.

N Engl J Med. 2006 May 18;354(20):2187; author reply 2187.

EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?

Crit Rev Oncol Hematol. 2016 Mar;99:170-9. doi: 10.1016/j.critrevonc.2015.12.006. Epub 2015 Dec 19.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Manageable early toxicity of cetuximab concurrent with radical radiotherapy for locally advanced head and neck cancer.

Clin Oncol (R Coll Radiol). 2011 Sep;23(7):496. doi: 10.1016/j.clon.2011.03.004. Epub 2011 Apr 11.

Cetuximab and radiotherapy for head and neck cancer.

N Engl J Med. 2006 Feb 9;354(6):634-6. doi: 10.1056/NEJMe058306.

More on cetuximab in head and neck cancer.

N Engl J Med. 2007 Nov 22;357(21):2201-2; author reply 2202-3. doi: 10.1056/NEJMc071540.

Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer.

Radiother Oncol. 2009 Dec;93(3):654. doi: 10.1016/j.radonc.2009.05.005. Epub 2009 Jun 11.

Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer.

Clin Oncol (R Coll Radiol). 2008 Nov;20(9):717. doi: 10.1016/j.clon.2008.07.003. Epub 2008 Aug 30.

Cetuximab plus radiotherapy for head and neck cancer.

N Engl J Med. 2006 May 18;354(20):2187; author reply 2187.

Cetuximab plus radiotherapy for head and neck cancer.

N Engl J Med. 2006 May 18;354(20):2187; author reply 2187.

Head and neck cancer: integrating anti-EGFR treatment with standard therapy.

J Natl Compr Canc Netw. 2004 Sep;2 Suppl 2:S52-9.

Cetuximab plus radiotherapy for head and neck cancer.

N Engl J Med. 2006 May 18;354(20):2187; author reply 2187.

EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?

Crit Rev Oncol Hematol. 2016 Mar;99:170-9. doi: 10.1016/j.critrevonc.2015.12.006. Epub 2015 Dec 19.